(redirected from Duloxetine hydrochloride)
Also found in: Medical.


A drug of the SNRI class, C18H19NOS, used in its hydrochloride form to treat depression, anxiety, fibromyalgia, and diabetic neuropathy.

[Perhaps du(al) (from its being a dual serotonin and norepinephrine reuptake inhibitor) + (flu)oxetine.]


n duloxetina
Mentioned in ?
References in periodicals archive ?
Case Report: Fulminant hepatic failure involving duloxetine hydrochloride.
Persons Reporting Prescriptions for 10 Leading Psychiatric Drugs (a) Drug Name Mechanism Rank (Brand Name) of Action 1 Sertraline hydrochlolride SSRI (Zoloft) antidepressant 2 Citalopram hydrobromide SSRI (Celexa) antidepressant 3 Alprazolam (Xanax) Benzodiazepine 4 Zolpidem tartrate (Ambien) Hypnotic 5 Fluoxetine hydrochloride SSRI (Prozac) antidepressant 6 Trazodone hydrochloride SARI (Desyrel) antidepressant 7 Clonazepam (Klonopin) Benzodiazepine 8 Lorazepam (Ativan) Benzodiazepine 9 Escitalopram oxalate SSRI (Lexapro) antidepressant 10 Duloxetine hydrochloride SNRI (Cymbalta) antidepressant Reported Use, Prescriptions per Rank No.
provided the medications used in the study: enteric-coated duloxetine hydrochloride tablets (20 mg/tablet; 20090401; Jiangsu Nhwa Pharmaceutical Co.
Duloxetine hydrochloride should not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease, according to a safety alert issued by the Food and Drug Administration and Eli Lilly & Co.
Postmarketing reports of duloxetine hydrochloride (Cymbalta), indicated for0 the treatment of major depressive disorder and diabetic peripheral neuropathic pain, suggest that patients with preexisting liver disease who take the drug may be at increased risk for further liver damage.
Approval of duloxetine hydrochloride by the Food and Drug Administration offers an additional drug for the treatment of major depressive disorder that affects both serotonin and norepinephrine.
Contract notice: Open-house discount contracts for drugs with the drug duloxetine hydrochloride (atc code n06ax21).
Aurobindo Pharma, a mid-size pharmaceutical company has won the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Duloxetine Hydrochloride Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base), which were earlier tentatively approved.